U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H24O3
Molecular Weight 288.3814
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Estriol

SMILES

C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1C[C@@H](O)[C@@H]2O

InChI

InChIKey=PROQIPRRNZUXQM-ZXXIGWHRSA-N
InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H24O3
Molecular Weight 288.3814
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02906111 | https://www.ncbi.nlm.nih.gov/pubmed/27838536 | https://clinicaltrials.gov/ct2/show/NCT02419729 | https://www.ncbi.nlm.nih.gov/pubmed/26786399 |

Estriol (E3), also spelled oestriol, is a steroid, a weak agonist of the estrogen receptors ERα and ERβ., and a minor female sex hormone. According to in vitro study, the relative binding affinity (RBA) of estriol for the human ERα and ERβ was 11.3% and 17.6% of that estradiol, respectively, and the relative transactivational capacity of estrone at the ERα and ERβ was 10.6% and 16.6% of that of estradiol, respectively. Estriol is marketed widely in Europe and elsewhere throughout the world under the brand names Ovestin, Ortho-Gynest, and a variety of others. It is available in oral tablet, vaginal cream, and vaginal suppository form, and is used in menopausal hormone therapy for the treatment of menopausal symptoms. Estriol is also available in some countries as estriol succinate (brand name Synapause), a dosage-equivalent ester prodrug of estriol. Estriol and estriol succinate are not approved for use in the United States and Canada, although they have been produced and sold by compounding pharmacies in North America for use as a component of bioidentical hormone therapy. Estriol can be measured in maternal blood or urine and can be used as a marker of fetal health and well-being. If levels of unconjugated estriol (uE3 or free estriol) are abnormally low in a pregnant woman, this may indicate chromosomal or congenital anomalies like Down syndrome or Edward's syndrome. It is included as part of the triple test and quadruple test for antenatal screening for fetal anomalies.

Originator

Sources: Journal of Biological Chemistry (1931), 91, 655-65.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Ovestin

Approved Use

Unknown
Primary
Ovestin

Approved Use

Unknown
Primary
Ovestin

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
60.57 pg/mL
20 μg single, vaginal
dose: 20 μg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
106.4 pg/mL
50 μg single, vaginal
dose: 50 μg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
13.77 pg/mL
20 μg 1 times / day steady-state, vaginal
dose: 20 μg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
22.8 pg/mL
50 μg 1 times / day steady-state, vaginal
dose: 50 μg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
0.546 nM
0.5 mg single, vaginal
dose: 0.5 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
ESTRIOL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
68 pg/mL
0.125 mg 1 times / day multiple, vaginal
dose: 0.125 mg
route of administration: Vaginal
experiment type: MULTIPLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
155 pg/mL
0.5 mg 1 times / day multiple, vaginal
dose: 0.5 mg
route of administration: Vaginal
experiment type: MULTIPLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
171.65 pg × h/mL
20 μg single, vaginal
dose: 20 μg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
406.75 pg × h/mL
50 μg single, vaginal
dose: 50 μg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
36.33 pg × h/mL
20 μg 1 times / day steady-state, vaginal
dose: 20 μg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
73.71 pg × h/mL
50 μg 1 times / day steady-state, vaginal
dose: 50 μg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2.145 nM × h
0.5 mg single, vaginal
dose: 0.5 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
ESTRIOL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
5643 pg × h/mL
0.125 mg 1 times / day multiple, vaginal
dose: 0.125 mg
route of administration: Vaginal
experiment type: MULTIPLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
18323 pg × h/mL
0.5 mg 1 times / day multiple, vaginal
dose: 0.5 mg
route of administration: Vaginal
experiment type: MULTIPLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.59 h
20 μg single, vaginal
dose: 20 μg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
1.65 h
50 μg single, vaginal
dose: 50 μg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
ESTRIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2.72 h
0.5 mg single, vaginal
dose: 0.5 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
ESTRIOL serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
ESTRIOL serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Other AEs: Vulvovaginal burning sensation, vulvovaginal burning sensation...
Other AEs:
Vulvovaginal burning sensation (9 patients)
vulvovaginal burning sensation (5 patients)
Vulvovaginal pruritus (2 patients)
Vaginal discharge (1 pt)
Vaginal haemorrhage (2 patients)
Genital burning sensation (2 patients)
Genital swelling (2 patients)
Nasopharyngitis (2 patients)
Application site pain (3 patients)
Nausea (1 pt)
Abdominal pain lower (2 patients)
Diarrhea (2 patients)
Nervous system disorders (1 pt)
Skin and subcutaneous tissue disorders (4 patients)
Renal and urinary disorders (2 patients)
Sources:
0.5 mg 1 times / day steady-state, vaginal
Recommended
Dose: 0.5 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.5 mg, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea 1 pt
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Nervous system disorders 1 pt
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Vaginal discharge 1 pt
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Abdominal pain lower 2 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Diarrhea 2 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Genital burning sensation 2 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Genital swelling 2 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Nasopharyngitis 2 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Renal and urinary disorders 2 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Vaginal haemorrhage 2 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Vulvovaginal pruritus 2 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Application site pain 3 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Skin and subcutaneous tissue disorders 4 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
vulvovaginal burning sensation 5 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Vulvovaginal burning sensation 9 patients
0.2 mg 1 times / day steady-state, vaginal
Highest studied dose
Dose: 0.2 mg, 1 times / day
Route: vaginal
Route: steady-state
Dose: 0.2 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Use of low potency estrogens does not reduce the risk of hip fracture.
2002-04
Reduced 11beta-hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight centile in pregnancies complicated by asthma.
2002-04
Steroid hormone levels during pregnancy and incidence of maternal breast cancer.
2002-04
Serial first- and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons.
2002-04
Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha.
2002-04
Effect of various oestrogens on cell injury and alteration of apical transporters induced by tert-butyl hydroperoxide in renal proximal tubule cells.
2002-03-22
Estradiol, testosterone, dehydroepiandrosterone and androstenedione: novel derivatives and enantiomers. Interactions with rat liver microsomal cytochrome P450 and antioxidant/radical scavenger activities in vitro.
2002-03-10
Information from your family doctor. Triple screening in pregnancy--what it is and what to expect.
2002-03-01
Maternal serum triple analyte screening in pregnancy.
2002-03-01
Pregnancy outcomes of women with positive serum screening results for Down syndrome and trisomy 18.
2002-03
Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21.
2002-03
Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia.
2002-03
Fetal diaphragmatic hernia and upper limb anomalies suggest Brachmann-de Lange syndrome.
2002-02
Treatment of bitches with acquired urinary incontinence with oestriol.
2002-01-26
A negative second trimester triple test and absence of specific ultrasonographic markers may decrease the need for genetic amniocentesis in advanced maternal age by 60%.
2002-01
Plasma corticotropin-releasing hormone and unconjugated estriol in human pregnancy: gestational patterns and ability to predict preterm delivery.
2002-01
Accuracy of expected risk of Down syndrome using the second-trimester triple test.
2002
Estradiol valerate/dienogest.
2002
Kinetic comparison of tissue non-specific and placental human alkaline phosphatases expressed in baculovirus infected cells: application to screening for Down's syndrome.
2002
Removal of endocrine-disrupting chemicals in activated sludge treatment works.
2001-12-15
Use of solid-phase extraction in various of its modalities for sample preparation in the determination of estrogens and progestogens in sediment and water.
2001-12-14
Sequential first and second trimester screening tests: correlation of the markers' levels in normal versus Down syndrome affected pregnancies.
2001-12
Plasma prolactin/oestradiol ratio at 38 weeks gestation predicts the duration of lactational amenorrhoea.
2001-12
Unconventional estrogens: estriol, biest, and triest.
2001-12
Identification of negative and positive estrogen response elements in human GnRH upstream promoter in the placental JEG-3 cells.
2001-11-26
A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function.
2001-11
Lens culinaris agglutinin-reactive alpha-fetoprotein, an alternative variant to alpha-fetoprotein in prenatal screening for Down's syndrome.
2001-11
[Health Council of Netherlands recommendation 'Serum screening for risk assessment of Down syndrome for all women' poorly supported].
2001-10-20
[Influence of hormonal replacement therapy on bacterial vaginosis in the group of peri- and postmenopausal women].
2001-10
ACOG Practice Bulletin. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetrician-gynecologists. Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001).
2001-10
Short term oral estriol treatment restores normal premenopausal vaginal flora to elderly women.
2001-09-28
Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens.
2001-09-14
[Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol].
2001-09
Effects of 17-beta estradiol and estriol on NMDA-induced toxicity and apoptosis in primary cultures of rat cortical neurons.
2001-09
Enhancement of collagen-induced arthritis in female mice by estrogen receptor blockage.
2001-09
Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening.
2001-09
Mammographic density changes during different postmenopausal hormone replacement therapies.
2001-09
Synthesis of ring B unsaturated estriols. Confirming the structure of a diagnostic analyte for Smith-Lemli-Opitz syndrome.
2001-08-09
Inhibition of large-conductance calcium-activated potassium channel by 2-methoxyestradiol in cultured vascular endothelial (HUV-EC-C) cells.
2001-08-01
Preterm birth risk assessment.
2001-08
Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement.
2001-08
Maternal serum screening for fetal trisomy 18: benefits of patient-specific risk protocol.
2001-08
Identification of 16alpha,19-dihydroxyandrostenedione in the serum of pregnant women by gas chromatography-mass spectrometry.
2001-08
An immunoassay for small analytes with theoretical detection limits.
2001-07-15
Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18.
2001-06
Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis.
2001-06
Determination of estradiol metabolites in human liver microsome by high performance liquid chromatography-electrochemistry detector.
2001-04
[Hormone replacement therapy in women with arterial hypertension in peri- and postmenopause: hemodynamic effects].
2001
Multiple marker second trimester serum screening for pre-eclampsia.
2001
Plasma levels and excretion of estrogens in urine in chronic lever disease.
1975-07
Patents

Sample Use Guides

1 g/daily of the vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
Route of Administration: Vaginal
TNBC cell lines HCC1806, HCC70 and MDA-MB-231 were used for activity evaluation. For stimulation of TNBC cells to analyze signal transduction of GPR30, 4×106 cells were plated in culture medium into 25 cm2 -culture flasks. After attachment, cells were serum starved for 24 hours to synchronize the 17β- estradiol-starved cells in G0-phase. Serum starved cells were treated for 30 minutes either with 10^−4 M estriol or solvent (0.1% ethanol) and subsequently stimulated with 10^−8 M 17β-estradiol in 0.1% ethanol for 10 min or 20 minutes. Cells were harvested and cell pellets lysed in 100 μl Cell lytic M (Sigma, Deisendorf, Germany), supplemented with protease-inhibitor (Sigma, Deisendorf, Germany) and phosphatase-inhibitor (Sigma, Deisendorf, Germany).
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:52:10 GMT 2025
Edited
by admin
on Mon Mar 31 17:52:10 GMT 2025
Record UNII
FB33469R8E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COLPOGYN
Preferred Name English
Estriol
EP   HSDB   MART.   MI   USP   USP-RS   WHO-DD  
Common Name English
ESTRIOL [JAN]
Common Name English
NSC-12169
Code English
ESTRIOL [EMA EPAR VETERINARY]
Common Name English
ESTRIOL [GREEN BOOK]
Common Name English
ESTRIOL [USP-RS]
Common Name English
AACIFEMINE
Common Name English
INCURIN
Brand Name English
ESTRIOL [USP MONOGRAPH]
Common Name English
ESTRIOL [EP MONOGRAPH]
Common Name English
TRIHYDROXYESTRIN
Common Name English
16.ALPHA.,17.BETA.-ESTRIOL
Common Name English
ESTRIOL [HSDB]
Common Name English
ESTRIOL [MART.]
Common Name English
16.ALPHA.-HYDROXYESTRADIOL
Code English
ESTRIOL [MI]
Common Name English
1,3,5-ESTRATRIENE-3B,16A,17B-TRIOL
Common Name English
13.BETA.-METHYL-1,3,5(10)-GONATRIENE-3,16.ALPHA.,17.BETA.-TRIOL
Systematic Name English
ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL, (16.ALPHA.,17.BETA.)-
Systematic Name English
Estriol [WHO-DD]
Common Name English
(16A,17B)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2181
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
WHO-ATC G03CC06
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 21264-7
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
LOINC 30510-2
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 43802-8
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 15064-9
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
LOINC 20466-9
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 2249-1
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
LOINC 14716-5
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
WHO-ATC G03CA04
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 2251-7
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
EMA VETERINARY ASSESSMENT REPORTS INCURIN [AUTHORIZED]
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
CFR 21 CFR 862.1265
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 2250-9
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
LOINC 27259-1
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
LOINC 16838-5
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LIVERTOX 374
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 32353-5
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 2248-3
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 14718-1
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
WHO-VATC QG03CA04
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 27225-2
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 34293-1
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 13737-2
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 34292-3
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
WHO-VATC QG03CC06
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 2252-5
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 21265-4
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 14717-3
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 44004-0
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
CFR 21 CFR 520.852
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
LOINC 2253-3
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
Code System Code Type Description
FDA UNII
FB33469R8E
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
PRIMARY
EPA CompTox
DTXSID9022366
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
DRUG CENTRAL
3187
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
PRIMARY
RS_ITEM_NUM
1254508
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
PRIMARY
ChEMBL
CHEMBL193482
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
CAS
50-27-1
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
HSDB
3590
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
NCI_THESAURUS
C80154
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
NSC
12169
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
PRIMARY
RXCUI
4094
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB04573
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
PUBCHEM
5756
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
WIKIPEDIA
Estriol (medication)
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
PRIMARY
SMS_ID
100000092668
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
PRIMARY
MESH
D004964
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
EVMPD
SUB01971MIG
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
MERCK INDEX
m5032
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY Merck Index
DAILYMED
FB33469R8E
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-022-2
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
CHEBI
27974
Created by admin on Mon Mar 31 17:52:11 GMT 2025 , Edited by admin on Mon Mar 31 17:52:11 GMT 2025
PRIMARY
WIKIPEDIA
Estriol
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
IUPHAR
2821
Created by admin on Mon Mar 31 17:52:10 GMT 2025 , Edited by admin on Mon Mar 31 17:52:10 GMT 2025
PRIMARY
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY